A detailed history of Royal London Asset Management LTD transactions in Abb Vie Inc. stock. As of the latest transaction made, Royal London Asset Management LTD holds 1,371,288 shares of ABBV stock, worth $230 Million. This represents 0.69% of its overall portfolio holdings.

Number of Shares
1,371,288
Previous 1,359,040 0.9%
Holding current value
$230 Million
Previous $233 Million 16.17%
% of portfolio
0.69%
Previous 0.6%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$163.84 - $199.33 $2.01 Million - $2.44 Million
12,248 Added 0.9%
1,371,288 $271 Million
Q2 2024

Aug 07, 2024

SELL
$154.79 - $180.76 $17.1 Million - $20 Million
-110,764 Reduced 7.54%
1,359,040 $233 Million
Q1 2024

May 14, 2024

BUY
$159.82 - $182.1 $15.2 Million - $17.3 Million
94,958 Added 6.91%
1,469,804 $268 Million
Q4 2023

Feb 13, 2024

BUY
$137.6 - $154.97 $12.9 Million - $14.5 Million
93,443 Added 7.29%
1,374,846 $213 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $12.3 Million - $14.3 Million
92,201 Added 7.75%
1,281,403 $191 Million
Q2 2023

Aug 11, 2023

BUY
$132.51 - $164.9 $25.6 Million - $31.8 Million
193,094 Added 19.38%
1,189,202 $160 Million
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $10 Million - $11.6 Million
69,437 Added 7.49%
996,108 $159 Million
Q4 2022

Feb 09, 2023

BUY
$138.31 - $165.87 $2.7 Million - $3.24 Million
19,534 Added 2.15%
926,671 $150 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $6.42 Million - $7.37 Million
-47,868 Reduced 5.01%
907,137 $122 Million
Q2 2022

Aug 12, 2022

SELL
$137.62 - $174.96 $427,447 - $543,425
-3,106 Reduced 0.32%
955,005 $147 Million
Q1 2022

May 13, 2022

BUY
$131.98 - $163.75 $9.72 Million - $12.1 Million
73,637 Added 8.33%
958,111 $155 Million
Q4 2021

Oct 18, 2022

SELL
$107.43 - $135.93 $4.63 Million - $5.86 Million
-43,115 Reduced 4.65%
884,474 $120 Million
Q4 2021

Jan 18, 2022

SELL
$107.43 - $135.93 $4.63 Million - $5.86 Million
-43,115 Reduced 4.65%
884,474 $120 Million
Q3 2021

Oct 18, 2022

SELL
$106.4 - $120.78 $2.04 Million - $2.31 Million
-19,163 Reduced 2.02%
927,589 $100 Million
Q3 2021

Nov 02, 2021

SELL
$106.4 - $120.78 $2.04 Million - $2.31 Million
-19,163 Reduced 2.02%
927,589 $100 Million
Q2 2021

Oct 18, 2022

SELL
$105.21 - $117.21 $868,298 - $967,334
-8,253 Reduced 0.86%
946,752 $107 Million
Q2 2021

Jul 14, 2021

SELL
$105.21 - $117.21 $2.8 Million - $3.12 Million
-26,631 Reduced 2.74%
946,752 $107 Million
Q1 2021

Oct 17, 2022

BUY
$102.3 - $112.62 $1.88 Million - $2.07 Million
18,378 Added 1.92%
973,383 $105 Million
Q1 2021

Apr 13, 2021

BUY
$102.3 - $112.62 $2.46 Million - $2.71 Million
24,070 Added 2.54%
973,383 $105 Million
Q4 2020

Jan 29, 2021

BUY
$80.49 - $108.67 $217,323 - $293,409
2,700 Added 0.29%
949,313 $102 Million
Q3 2020

Nov 04, 2020

BUY
$85.91 - $100.83 $1.59 Million - $1.87 Million
18,521 Added 2.0%
946,613 $82.2 Million
Q2 2020

Jul 31, 2020

BUY
$73.37 - $98.18 $6.26 Million - $8.38 Million
85,373 Added 10.13%
928,092 $89.5 Million
Q1 2020

May 01, 2020

BUY
$64.5 - $97.79 $694,213 - $1.05 Million
10,763 Added 1.29%
842,719 $63.4 Million
Q4 2019

Feb 05, 2020

BUY
$72.13 - $90.25 $1.23 Million - $1.54 Million
17,052 Added 2.09%
831,956 $73.6 Million
Q3 2019

Nov 12, 2019

SELL
$62.98 - $75.72 $396,459 - $476,657
-6,295 Reduced 0.77%
814,904 $61.7 Million
Q2 2019

Jul 31, 2019

SELL
$65.7 - $83.98 $389,272 - $497,581
-5,925 Reduced 0.72%
821,199 $59.7 Million
Q1 2019

Apr 30, 2019

BUY
$77.14 - $90.79 $2.12 Million - $2.49 Million
27,428 Added 3.43%
827,124 $0
Q4 2018

Jan 29, 2019

BUY
$77.85 - $96.01 $12 Million - $14.8 Million
153,773 Added 23.81%
799,696 $72.9 Million
Q3 2018

Nov 08, 2018

SELL
$88.91 - $98.84 $2.79 Million - $3.1 Million
-31,357 Reduced 4.63%
645,923 $0
Q2 2018

Sep 19, 2018

BUY
$89.78 - $106.23 $60.8 Million - $71.9 Million
677,280 New
677,280 $62.8 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $297B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Royal London Asset Management LTD Portfolio

Follow Royal London Asset Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal London Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Royal London Asset Management LTD with notifications on news.